miércoles, 18 de noviembre de 2026
FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer
https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-neladalkib-previously-treated-locally-advanced-or-metastatic-alk?utm_medium=email&utm_source=govdelivery
On November 17, 2026, the Food and Drug Administration granted accelerated approval to neladalkib (Nelkarmi, Nuvalent, Inc.), a kinase inhibitor, for adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received the following therapy in the unresectable locally advanced or metastatic setting:
one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or
two or more prior ALK TKIs and platinum-based chemotherapy.
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario